Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights

Executive Summary

The new molecular entity and novel biologic class of 2011 isn’t just the largest since 2004 – CDER also posted near-perfect on-time review performance while maintaining healthy rates of first-cycle approvals and a low 15 month average time to approval, thanks to a high level of innovation in the novel product candidates.

Advertisement

Related Content

First-In-Class Drugs Are True Barometer Of Industry Innovation, FDA Says
Generic Drugs’ 10-Year Savings To U.S. Health System Top $1 Tril. For First Time, GPhA Finds
GAO Gives FDA Drug Review Performance Seal Of Approval
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
Emerging Sponsors And FDA: Will Better Communication Under PDUFA V Ease Inherent Tensions?
FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents
FDA Initiatives To Expedite Reviews Pay Off In FY’11 Approvals
FDA Sets A Fast Pace Of Novel Approvals In First Half, But That's Likely To Slow
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel